Beta-thalassemia cost-effectiveness of therapy

Beta-thalassemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Beta-thalassemia from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Beta-thalassemia cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Beta-thalassemia cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Beta-thalassemia cost-effectiveness of therapy
CDC on Beta-thalassemia cost-effectiveness of therapy
Beta-thalassemia cost-effectiveness of therapy in the news
Blogs on Beta-thalassemia cost-effectiveness of therapy
Directions to Hospitals Treating Beta-thalassemia
Risk calculators and risk factors for Beta-thalassemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as access to healthcare resources, availability of blood products, affordability of chelation therapy, and overall disease management.

Cost-effectiveness of therapy

The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as:

• Access to healthcare resources
• Availability of blood products
• Affordability of chelation therapy
• Overall disease management

References

Template:WikiDoc Sources